Allergy Therapeutics plc (AGY.L)
| Previous close | 22.00 |
| Open | 21.00 |
| Bid | 21.00 x 0 |
| Ask | 23.00 x 0 |
| Day's range | 21.00 - 22.16 |
| 52-week range | 20.02 - 40.50 |
| Volume | |
| Avg. volume | 96,145 |
| Market cap | 141.68M |
| Beta (5Y monthly) | 1.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.80 |
| Earnings date | 03 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 59.00 |
- Globe Newswire
Interim Results for the six months ended 31 December 2021
Allergy Therapeutics plc(“Allergy Therapeutics” or the “Company” or the “Group”) Interim Results for the six months ended 31 December 2021 ~ US readiness plan underway including two pivotal trials Portfolio focused on high value growth products to enhance future profitabilityGround-breaking Phase I trial of peanut allergy vaccine on track to commence in 2022 following recent FDA clearance of IND application with data expected sooner than previously anticipatedPivotal Phase III trial of short-cou
- Simply Wall St.
Allergy Therapeutics' (LON:AGY) investors will be pleased with their decent 79% return over the last three years
It hasn't been the best quarter for Allergy Therapeutics plc ( LON:AGY ) shareholders, since the share price has fallen...
- Globe Newswire
Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut
Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”) Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut Paves the way for start of VLP Peanut vaccine candidate’s Phase I PROTECT trial in H1 2022Topline data from first-in-human trial expected in H1 2023Analysis of data from earlier ex-vivo biomarker study, VLP001, demonstrates beneficial mode of action of the vaccine candidate 26 January 2022 Allergy Therapeutics
